SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial.

SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial.

To confirm safety and feasibility of hypofractionated SBRT for early-stage glottic laryngeal cancer.Twenty consecutive patients with cTis-T2N0M0 carcinoma of glottic larynx were enrolled. Patients entered dose-fractionation cohorts of incrementally shorter bio-equivalent schedules starting with 50 G...

Full description

Bibliographic Details
Main Authors: David L Schwartz, Alan Sosa, Stephen G Chun, Chiuxiong Ding, Xian-Jin Xie, Lucien A Nedzi, Robert D Timmerman, Baran D Sumer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5333979?pdf=render

Similar Items

Similar Items